AstraZeneca has acquired all of Biovitrum‘s rights to its leptin modulator program aimed at treating obesity. Biovitrum will receive from AstraZeneca an upfront payment of $9 million and milestone payments contingent on development progress and sales, as well as single-digit percentage royalties. If a product is approved, the agreement caps out at a total of $280 million in upfront and milestone payments to Biovitrum. The leptin modulator program is currently in the preclinical phase. B...